Experienced biotech CFO to lead financial strategy and contribute to the Company's next stage of growth
Company preparing to initiate comprehensive Phase 3 program for chronic cough in patients with idiopathic pulmonary fibrosis in first half of 2026
Conference call and webcast to be held at 4:30 p.m. ET
Fireside Chat with Management on Tuesday, November 11, 2025, at 3:20 p.m. ET
Trevi Therapeutics ((TRVI)) announced an update on their ongoing clinical study.Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced...
Professor Philip Molyneaux will give an oral presentation on the key efficacy and safety results from the Phase 2b CORAL trial of nalbuphine ER for the treatment of chronic cough in patients with idiopathic...
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on MoonLake Immunotherapeutics (MLTX – Research Report), Trevi Therapeutics (TRVI – Research Report) and...
Leerink Partners analyst Faisal Khurshid reiterated a Buy rating on Trevi Therapeutics on September 29. The company’s shares closed yesterday at $9.56.Elevate Your Investing Strategy: Take advantage...
NEW HAVEN, Conn. , Sept. 18, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™...
NEW HAVEN, Conn. , Aug. 28, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™...